Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG [PGG glucan] Injection in Healthy Adult Subjects

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG [PGG glucan] Injection in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odetiglucan (Primary)
  • Indications Chronic lymphocytic leukaemia; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Postoperative infections
  • Focus Adverse reactions
  • Sponsors Biothera

    • Most Recent Events

    • 25 Feb 2016 Results published in Investigational New Drugs: The Journal of New Anticancer Agents, as per Biothera media release.
    • 25 Feb 2016 Results published in Biothera media release.
    • 31 Oct 2008 Data will be presented at the International Society for Biological Therapy of Cancer on 01 November 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top